CREON Per Meal Dosing Guide

This dosing guide can help you determine the recommended weight-based per meal dosing for your patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.

CREON® is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1

Dosage recommendations for pancreatic enzyme replacement therapy were published following the Cystic Fibrosis Foundation Consensus Conferences.

Patients should be advised that the total daily dose should not exceed 10,000 lipase units/kg body weight/day unless clinically indicated. CREON dosage should be individualized and adjusted based on the clinical symptoms, degree of steatorrhea present, and the fat content of the diet. Instruct patients and caregivers that CREON should only be taken as directed by their healthcare professional. CREON should always be taken with food. CREON should not be crushed or chewed. If a CREON dose is missed, the next dose should be taken with the next meal. Doses should not be doubled. Usually, half of the prescribed CREON dose for an individualized full meal should be given with each snack.


INFANTS
(<12 months)

Although the Cystic Fibrosis Foundation Consensus Conferences recommend doses of 2,000 to 4,000 lipase units in infants up to 12 months, CREON is available in a 3,000 lipase unit capsule. Therefore, the recommended dose of CREON in infants up to 12 months is 3,000 lipase units per 120 mL of formula or per breast-feeding.


CHILDREN
(>12 months to <4 years)
Select Weight
Recommended Dosing
Maximum
Lipase Units
0
Minimum
Lipase Units
0

INDIVIDUALS
(>4 years)
Select Weight
Recommended Dosing
Maximum
Lipase Units
0
Minimum
Lipase Units
0

 

IMPORTANT SAFETY INFORMATION

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

INDICATIONS

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Reference:
  1. CREON [package insert].

OTHER TOPICS


CREON Dosing

See CREON dosing guidelines.

Patient & HCP Resources

Support for you and your patients in managing EPI and CF.

CREON Co-pay Assistance

Make sure your patients receive the CREON co-pay card.